1. Home
  2. SBFG vs CRDF Comparison

SBFG vs CRDF Comparison

Compare SBFG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$20.02

Market Cap

134.8M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.79

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
CRDF
Founded
1983
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.8M
130.7M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
SBFG
CRDF
Price
$20.02
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
9.2K
689.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.10%
N/A
EPS Growth
27.33
27.37
EPS
2.19
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.10
N/A
Revenue Growth
N/A
49.61
52 Week Low
$17.10
$1.48
52 Week High
$23.93
$4.56

Technical Indicators

Market Signals
Indicator
SBFG
CRDF
Relative Strength Index (RSI) 38.22 43.24
Support Level $19.69 $1.51
Resistance Level $21.60 $2.05
Average True Range (ATR) 0.49 0.12
MACD -0.01 0.00
Stochastic Oscillator 35.51 16.92

Price Performance

Historical Comparison
SBFG
CRDF

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: